Entero Healthcare Solutions

Entero Healthcare delivered a strong Q3 FY26Current reported value: 26. No comparable prior figure is available in the source record. with revenue of ₹1,771 croreCurrent reported value: ₹1,771 crore. No comparable prior figure is available in the source record. (+26% YoY) and EBITDA of ₹68 croreCurrent reported value: ₹68 crore. No comparable prior figure is available in the source record. (+36% YoY), driven by organic growth of 17.1%Current 17.1%. Reported change: +17.1pp YoY. and contributions from recent medtech acquisitions. Gross margin expanded 30bps to 10.1%, while EBITDA margin improved 30bps to 4Current reported value: 4. No comparable prior figure is available in the source record.%. PAT (adjusted for one-off labor code impact) grew 36% to ₹40 crore. Operating cash flow turned positive at ₹49 croreCurrent reported value: ₹49 crore. No comparable prior figure is available in the source record., a sharp improvement from -₹21 crore last year, aided by working capital days reducing to 61. Management reiterated full-year guidance of 30% like-to-like revenue growth, 4%+ EBITDA margin, and OCF of ₹100 crore. The medtech segment, now annualizing over ₹1,000 crore, is expected to add 50-75bps to EBITDA margins. Risk: Integration of multiple acquisitions could strain margins if cost synergies fail to materialize as expected.